Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 Treatment

NCT06076135 is registered in ClinicalTrials.gov with Chuangzhen Chen as lead sponsor.

NCT NCT06076135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06076135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy and PD-1/PD-L1 Inhibitors for Metastatic Malignant Solid Tumors After Acquired Resistance to Anti-PD1/PD-L1 Treatment
Lead sponsor
Chuangzhen Chen
Phase
Phase 2
Overall status
Completed
Start date
December 26, 2023
Completion date
May 10, 2026
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint blockade, metastatic malignant solid neoplasm, radiotherapy, resistance to immunotherapy